ERBB2 and breast carcinoma: In a suitable breast cancer preclinical model, we demonstrated that HER2-positive tumors that are de novo resistant to trastuzumab, an anti-HER2 monoclonal antibody used as a first line treatment for patients with this type of cancer, are sensitized when sTNFα is blocked with INB03 in combination with trastuzumab (203) (Figure 5).